Carcinoid syndrome is the collection of symptoms some people get when a neuroendocrine tumour, usually one that has spread to the liver, releases hormones such as serotonin into the bloodstream. It is predominantly associated with neuroendocrine tumors (NETs) that arise from the mid-gut in the setting of extensive liver metastases but may be present in patients with bronchial carcinoids, and more rarely, in patients with pancreatic NETs. Carcinoid tumors most commonly occur in the small intestine and appendix, but 10% originate in the lung. Other affected areas include the rectum, colon, pancreas, stomach, ovary, thymus, kidney, prostate, breast and elsewhere.
Affected people with carcinoid syndrome may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, it may cause damage to the heart valves, resulting in symptoms of congestive heart failure.
The symptoms of carcinoid syndrome include episodes of warmth and redness of the face, head and upper chest; diarrhea; marked changes in blood pressure (usually hypotension, a decrease in blood pressure); asthmatic-like wheezing; weight loss or gain; malnutrition; dehydration; weakness; muscle and joint aching; and peptic ulcer.
Get FREE sample copy at:
The Carcinoid Syndrome market report also covers emerging drugs, current treatment practices, Carcinoid Syndrome market share of the individual therapies, current and forecasted Carcinoid Syndrome Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Carcinoid Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Carcinoid Syndrome Market Key Facts
As per the National Organization for Rare Disorders estimates around 27 new cases of Carcinoid Tumour per million are diagnosed in the United States per year out of which, only about 10% develop carcinoid syndrome.
According to the study conducted by Pandit et al., flushing is the most common presentation and occurs in about 85% of patients with Carcinoid Syndrome and diarrhea occurs in about 80% of cases (Diarrhea is usually chronic in carcinoid syndrome).
Key Benefits of Carcinoid Syndrome Market Report
Carcinoid Syndrome market report provides an in-depth analysis of Carcinoid Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Carcinoid Syndrome market report will help in developing business strategies by understanding the Carcinoid Syndrome Market trends & developments, key players and future market competition that will shape and drive the Carcinoid Syndrome market in the upcoming years.
The Carcinoid Syndrome market report covers Carcinoid Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Carcinoid Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Due to various side effects of currently available therapies/medication, there is a demand for new therapies in the market with no or minimal adverse effects and provide proper treatment to the patients suffering from Carcinoid Syndrome. Owing to the launch of upcoming therapies, the market size shall grow during forecast period.
The Carcinoid Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Carcinoid Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Carcinoid Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
As per the study conducted by Alur et al. (2017), it is estimated that only about 10% of neuroendocrine tumors result into carcinoid syndrome. Carcinoid-syndrome is characterized by the presence during the disease at some time of diarrhea, cutaneous flushing, wheezing/asthma-like symptoms, and pellagra-like skin lesions with hyperkeratosis and pigmentation. In Canada, carcinoid tumors represent less than 0.25% of the oncology patient load.
The Carcinoid Syndrome epidemiology section covers insights about historical and current Carcinoid Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Carcinoid Syndrome Drugs Uptake and Key Market Players
The Carcinoid Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Carcinoid Syndrome market or expected to get launched in the market during the study period. The analysis covers Carcinoid Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
key players in the Carcinoid Syndrome market:
Table of Content
1. Key Insights
2. Executive Summary
3. Carcinoid Syndrome Competitive Intelligence Analysis
4. Carcinoid Syndrome Market Overview at a Glance
5. Carcinoid Syndrome Disease Background and Overview
6. Carcinoid Syndrome Patient Journey
7. Carcinoid Syndrome Epidemiology and Patient Population
8. Carcinoid Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Carcinoid Syndrome Unmet Needs
10. Key Endpoints of Carcinoid Syndrome Treatment
11. Carcinoid Syndrome Marketed Products
12. Carcinoid Syndrome Emerging Therapies
13. Carcinoid Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Carcinoid Syndrome Market Outlook (7 major markets)
16. Carcinoid Syndrome Access and Reimbursement Overview
17. KOL Views on the Carcinoid Syndrome Market.
18. Carcinoid Syndrome Market Drivers
19. Carcinoid Syndrome Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Carcinoid Syndrome Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Carcinoid Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Carcinoid Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Carcinoid Syndrome market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States